Skip to content
Feral Cat LogoGovInfoNow
FDA drug shortage status

Is Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection (Recarbrio) in shortage?

Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection is listed by FDA as being discontinued by at least one maker (updated Sep 9, 2026).

Being discontinuedFDA status
1packages listed
0unavailable

Every listed package

FDA tracks shortages per package. What each maker reports, most recently updated first:

  • RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)
    Merck Sharp & Dohme LLCBeing discontinuedUpdated Sep 9, 2026Discontinued Sep 9, 2026

    To be discontinued on or near late September 2026.

    Maker contact: 800-672-6372

Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection shortage questions

Is Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection (Recarbrio) in shortage?

Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection is listed by FDA as being discontinued by at least one maker (updated Sep 9, 2026).

What should I do if I can’t get Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection?

Don’t stop or ration it on your own. Ask your pharmacist whether another strength, package size or maker is in stock, and ask your prescriber about an alternative if none is.

Source: FDA Drug Shortages Database via openFDA. FDA notes that openFDA data is unvalidated and should not be used to make decisions about medical care; ask your pharmacist or prescriber before changing any medication. FDA Drug Shortages Database.